Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration01:25

Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration

361
Hemoperfusion and hemofiltration are critical techniques in medical treatments to eliminate accumulated drugs, metabolites, and electrolytes from the bloodstream. These methods are particularly vital in cases of accidental poisoning and drug overdose.Hemoperfusion involves passing blood through an adsorbent material to remove unwanted substances. The main adsorbents used in hemoperfusion include activated charcoal and Amberlite resins. Activated charcoal can adsorb both polar and nonpolar...
361
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

388
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
388

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibition of the ZEB1-BCL2 axis in cancer-associated fibroblasts as a strategy to improve chemotherapy response in intrahepatic cholangiocarcinoma.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Treatment of Hypovitaminosis D Is Associated with Improvement in Anemia of Inflammation in Patients with Decompensated Cirrhosis.

Medical sciences (Basel, Switzerland)·2026
Same author

Clinical Efficacy and Safety of Multiple High-Dose Antibiotic-Loaded Cement Spacers in the Two-Stage Revision of Gram-Positive Periprosthetic Joint Infection.

Microorganisms·2026
Same author

Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma.

Cancer cell·2026
Same author

Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort study.

Lancet (London, England)·2026
Same author

Development and validation of the A-TANGO organ failure score for acute-on-chronic liver failure in global cohorts.

Journal of hepatology·2026

Related Experiment Video

Updated: Apr 20, 2026

Decellularization and Recellularization of Whole Livers
09:24

Decellularization and Recellularization of Whole Livers

Published on: February 4, 2011

22.7K

Molecular adsorbent recirculating system and bioartificial devices for liver failure.

Rafael Bañares1, María-Vega Catalina2, Javier Vaquero2

  • 1Gastroenterology and Hepatology Department, Hospital General Universitario Gregorio Marañón, IiSGM, Madrid, Spain; Centro de investigación en red de enfermedades hepáticas y digestivas (CIBEREHD), Barcelona, Spain; School of Medicine, Universidad Complutense de Madrid (UCM), Madrid, Spain.

Clinics in Liver Disease
|December 2, 2014
PubMed
Summary

Extracorporeal liver support systems aim to aid acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) patients. While showing promise in reducing toxins and improving symptoms, their impact on patient survival remains unproven.

Keywords:
Acute liver failureAcute-on-chronic liver failureAlbumin dialysisExtracorporeal liver assist deviceHepatic encephalopathy

More Related Videos

A Novel Surgical Technique As a Foundation for In Vivo Partial Liver Engineering in Rat
13:27

A Novel Surgical Technique As a Foundation for In Vivo Partial Liver Engineering in Rat

Published on: October 6, 2018

8.7K
Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure
16:19

Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure

Published on: September 13, 2014

13.4K

Related Experiment Videos

Last Updated: Apr 20, 2026

Decellularization and Recellularization of Whole Livers
09:24

Decellularization and Recellularization of Whole Livers

Published on: February 4, 2011

22.7K
A Novel Surgical Technique As a Foundation for In Vivo Partial Liver Engineering in Rat
13:27

A Novel Surgical Technique As a Foundation for In Vivo Partial Liver Engineering in Rat

Published on: October 6, 2018

8.7K
Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure
16:19

Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure

Published on: September 13, 2014

13.4K

Area of Science:

  • Hepatology
  • Biomedical Engineering
  • Critical Care Medicine

Background:

  • Acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) present significant clinical challenges with high morbidity and mortality rates.
  • Current treatments are limited, necessitating innovative solutions for liver support.

Purpose of the Study:

  • To review the current status and potential of extracorporeal liver support systems for managing ALF and ACLF.
  • To evaluate the efficacy and limitations of artificial (cell-free) and bioartificial liver support devices.

Main Methods:

  • Review of existing literature on artificial and bioartificial liver support systems.
  • Analysis of reported outcomes regarding toxin reduction, hepatic encephalopathy amelioration, and patient survival.

Main Results:

  • Artificial and bioartificial liver support devices have demonstrated an ability to reduce circulating toxins.
  • These systems have shown potential in improving intermediate variables such as hepatic encephalopathy.
  • The safety profile of these devices has generally been found to be acceptable.

Conclusions:

  • Extracorporeal liver support systems offer a potential therapeutic avenue for ALF and ACLF.
  • Despite demonstrated benefits in toxin clearance and symptom management, conclusive evidence of improved patient survival is still lacking.
  • Further research and development are needed to optimize these devices for clinical application and survival benefit.